KRAS and neoplasm: In an HCT-8 (KRAS G13D) xenograft model, PrP<sup>C</sup> monotherapy inhibited tumor growth in a dose-dependent manner, and 5-fluorouracil (5-FU) monotherapy produced an intermediate effect.